Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study

Shaji K. Kumar, Jesus G. Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P. Laubach, Mehdi Hamadani, A. Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L. Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai Min Hui, Vincent Rajkumar, Paul G. Richardson

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences